References
- Wiedersberg S, Leopold CS, Guy RH. (2008). Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm, 68:453–466.
- Center for Drug Evaluation and Research (1998). Draft guidance: topical dermatological drug product NDAs and ANDAs-in vivo bioavailability, bioequivalence, in vitro release, and associated studies. United States Food and Drug Administration.
- N’Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. (2008). Optimizing metrics for the assessment of bioequivalence between topical drug products. Pharm Res, 25:1621–1630.
- N’Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. (2009). Improved bioequivalence assessment of topical dermatological drug products using dermatopharmacokinetics. Pharm Res, 26:316–328.
- Bunge AL, Guy RH. Dermatopharmacokinetics; improvement of methodology for assessing bioequivalence of topical products: presentation to FDA advisory committee for pharmaceutical science, October 2003, FDA 2003.
- Alberti I, Kalia YN, Naik A, Guy RH. (2001). Assessment and prediction of the cutaneous bioavailability of topical terbinafine, in vivo, in man. Pharm Res, 18:1472–1475.
- Pirot F, Kalia YN, Stinchcomb AL, Keating G, Bunge A, Guy RH. (1997). Characterization of the permeability barrier of human skin in vivo. Proc Natl Acad Sci USA, 94:1562–1567.
- Hansen S, Henning A, Naegel A, Heisig M, Wittum G, Neumann D et al. (2008). In-silico model of skin penetration based on experimentally determined input parameters. Part I: experimental determination of partition and diffusion coefficients. Eur J Pharm Biopharm, 68:352–367.
- Nicoli S, Bunge AL, Delgado-Charro MB, Guy RH. (2009). Dermatopharmacokinetics: factors influencing drug clearance from the stratum corneum. Pharm Res, 26:865–871.
- Schmook FP, Meingassner JG, Billich A. (2001). Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int J Pharm, 215:51–56.
- Jacobi U, Kaiser M, Toll R, Mangelsdorf S, Audring H, Otberg N et al. (2007). Porcine ear skin: an in vitro model for human skin. Skin Res Technol, 13:19–24.
- Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH. (2006). Pig ear skin ex vivo as a model for in vivo dermatopharmacokinetic studies in man. Pharm Res, 23:1850–1856.
- McClellan KJ, Wiseman LR, Markham A. (1999). Terbinafine. An update of its use in superficial mycoses. Drugs, 58:179–202.
- Kyle AA, Dahl MV. (2004). Topical therapy for fungal infections. Am J Clin Dermatol, 5:443–451.
- Bimbaum JE. (1990). Pharmacology of the allylamines. J Am Acad Dermatol, 23:782–785.
- Noguchi H, Hiruma M, Kawada A. (1999). Effectiveness of treatment of severe tinea pedis with 1% terbinafine cream in members of the Japanese self-defense forces. Mycoses, 42:479–484.
- Berman B, Ellis C, Leyden J, Lowe N, Savin R, Shupack J et al. (1992). Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis. Results of placebo-controlled, double-blind, multicenter trials. J Am Acad Dermatol, 26:956–960.
- Dick IP, Scott RC. (1992). Pig ear skin as an in-vitro model for human skin permeability. J Pharm Pharmacol, 44:640–645.